FDA Asks for Input on Post-Market Drug Safety Reporting
Published Date: 5/13/2026
Notice
Summary
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
Analyzed Economic Effects
6 provisions identified: 1 benefits, 5 costs, 0 mixed.
Mandatory ICH E2B(R3) Data Standard
If you submit postmarketing individual case safety reports (ICSRs) via FDA's Electronic Submissions Gateway Next Generation (ESG NextGen), those ICSRs must use the ICH E2B(R3) data standards beginning October 1, 2026. FDA began accepting E2B(R3) voluntarily in January 2024 and is now requiring the R3 standard on that date.
10- and 6-Year Recordkeeping Rules
Applicants and manufacturers must keep adverse drug experience records for 10 years under 21 CFR 314.80(j) and 310.305(g). For nonprescription human drug products under section 760(e), responsible persons must retain nonprescription adverse event records for 6 years.
Enhanced Pharmacovigilance Requests by FDA
FDA's January 2024 'Best Practices' may lead to enhanced pharmacovigilance activities for specific products; FDA may request use of targeted data collection tools, expedited submission of adverse experiences beyond minimum reporting, and summarization/assessment at FDA-defined frequencies. FDA has included burden estimates for these enhanced activities in its tables.
Periodic Report Timing Requirement
For approved drug applications, periodic postmarketing safety reports must be submitted quarterly for the first 3 years after U.S. approval and annually thereafter, per 21 CFR 314.80(c)(2) and 600.80(c)(2). These reports must include narratives, summaries, analyses, and indexes of adverse experiences.
5-Day Combination-Product Notification Rule
If a combination product event involves a drug and a constituent applicant receives information about a death, serious injury, or adverse event, that information must be provided to other constituent part applicants no later than 5 calendar days after receipt under 21 CFR 4.103. Rules for submission and recordkeeping for combination products are in 21 CFR 4.104 and 4.105.
Electronic Submission Waivers for Good Cause
All reports and followup reports generally must be submitted electronically, but FDA may grant temporary waivers of the electronic submission requirements for good cause. Waiver requests can be submitted under the cited regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09283 — Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate
The FDA is inviting vets, animal drug makers, and animal lovers to join meetings about renewing the Animal Drug User Fee Act before it expires in 2028. These meetings, starting June 2026 and happening every four months, will help decide how fees for animal drug reviews are set and used. If you want to have a say, let the FDA know by June 1, 2026!
Previous / Next Documents
Previous: 2026-09542 — Agency Information Collection Activity Under OMB Review: Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program (SSG Fox SPGP)
The VA is renewing its paperwork for the Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program, which helps communities support veterans at risk of suicide. This means organizations applying for or renewing grants will keep submitting forms to show how they’re helping and following rules. If you’re involved, get ready to send your feedback by June 12, 2026, so the program can keep saving lives smoothly and smartly.
Next: 2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.